Laboratory Specimen Transport Best Practices

Article

Laboratory Specimen Transport Best Practices

Specimen transport is a critical part of laboratory quality management, not a simple handoff between a collection site and a testing facility. Approximately 60–70% of laboratory errors originate in the pre-analytical phase, before a specimen reaches the analyzer. A reliable process must protect specimen integrity, preserve patient privacy, document custody, and meet applicable OSHA and U.S. Department of Transportation (DOT) requirements. Healthcare organizations should define transport standards by specimen type, stability window, packaging classification, and service-level expectations.

Pre-Analytical Risks and Specimen Labeling

The pre-analytical phase includes patient and test identification, specimen collection, labeling, packaging, storage, and transport. Each step can introduce an error that cannot be corrected by laboratory instrumentation. Transport-related failures commonly include temperature excursions, physical trauma that causes hemolysis, delays beyond the specimen’s stability window, and gaps in chain-of-custody documentation.

Before handoff, the collection site should label every specimen with at least two patient identifiers, typically the patient’s full name plus medical record number or date of birth. The collection date and time must be recorded because the laboratory uses them to calculate stability and determine whether a specimen remains suitable for testing. The tube type should be visible on the outer packaging or transport pouch without requiring unnecessary handling. A laboratory accession number or scannable barcode supports positive identification and creates an electronic chain-of-custody event.

A courier should not accept a specimen with an unreadable, incomplete, or mismatched label. Mislabeled specimens may be rejected, requiring a repeat collection and delaying treatment. In more serious circumstances, an identification error can contribute to an incorrect diagnosis, inappropriate therapy, transfusion risk, or other patient harm. HIPAA privacy safeguards also apply during transport; containers, manifests, and electronic systems should limit access to protected health information to the minimum necessary for the delivery.

Temperature and Stability Controls by Specimen Type

Temperature requirements must be based on the laboratory’s validated test directory and the assay manufacturer’s instructions. General handling categories include:

Whole blood for a CBC or differential is commonly maintained at room temperature, approximately 18–25°C, and may remain stable for about 24 hours, although individual laboratory validation and analyzer requirements control.

Serum or plasma for many chemistry panels is generally refrigerated at 2–8°C after appropriate clotting and separation instructions are followed.

Coagulation specimens for PT/INR and aPTT are generally maintained at room temperature and processed within four hours. Some tests require faster processing or platelet-poor plasma preparation.

Molecular and PCR specimens may require frozen transport at -20°C or -80°C, depending on the assay, specimen medium, and laboratory protocol. Repeated freeze-thaw cycles should be avoided.

Tissue and biopsy specimens must follow pathology instructions, such as placement in validated formalin fixation or transport on ice when fresh tissue is required. Formalin specimens must not be frozen unless the pathology protocol specifically directs it.

Timing can be as significant as temperature. Coagulation specimens degrade quickly and should reach processing within the defined four-hour room-temperature window. Blood gas samples typically require immediate analysis; if a short delay is unavoidable, the laboratory may require transport on ice, subject to its validated protocol. Glucose can decline in unseparated whole blood at approximately 0.05 mmol/L per hour at room temperature, with the rate varying by cellular content and conditions. A sodium fluoride tube or processing within 30 minutes may be required for accurate results.

When a courier misses a pickup window, the laboratory may face a rejected specimen, a recollection, delayed clinical decisions, or a result that must be qualified because stability cannot be confirmed. A defined temperature-controlled transport program should specify packaging, monitoring, pickup cutoffs, escalation procedures, and contingency service for delays.

UN3373 Packaging and Regulatory Compliance

Most routine diagnostic specimens are shipped as UN3373 Biological Substance, Category B under DOT rules in 49 CFR 173.199. The packaging system requires three layers. The primary container, such as a specimen tube or vial, must be leak-proof and securely closed. Absorbent material must be placed between the primary container and the secondary packaging in sufficient quantity to absorb the entire contents if leakage occurs.

The secondary container must be rigid or otherwise protective and leak-proof. It should prevent movement, protect tubes from breakage, and maintain the required temperature with qualified coolant or insulation when needed. The outer package must be durable for normal transportation conditions and display the UN3373 diamond mark with the wording “Biological Substance, Category B.” Orientation markings may be required for liquid specimens, and the package should include the shipper and consignee information required by the applicable transport method.

Category A classification applies when exposure to the substance can cause permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals. Category A infectious substances follow more stringent packaging, marking, documentation, training, and transport requirements under DOT regulations, including applicable provisions in 49 CFR 173.196 and 173.197. The shipper, not the courier alone, is responsible for correctly classifying the material. OSHA’s Bloodborne Pathogens Standard, 29 CFR 1910.1030, also requires employers to use appropriate work practices, containers, labeling, training, and exposure controls for occupational handling.

Chain of Custody at Pickup

Chain of custody begins at the collection site, not when the specimen arrives at the laboratory. The courier should verify and document the specimen or shipment ID, collection site name, handler name, pickup date and time, number of containers, packaging condition, and temperature at pickup when temperature control is required. An electronic scan creates the first custody event and should link the specimen to the route, courier, and destination.

The pickup receipt should identify each shipment or accession number, origin and destination, pickup timestamp, package count, temperature reading or acceptable range, and any exception such as damaged packaging, missing paperwork, or an out-of-range temperature. The receiving laboratory should obtain a delivery timestamp, recipient identity, package condition, and temperature at receipt. Detailed chain of custody documentation supports investigation, HIPAA accountability, quality reporting, and defensible resolution of disputes.

Auditing Courier Performance and Contract SLAs

Laboratory leaders should review specimen rejection data by reason code, courier, route, collection site, and time of day. Useful codes include unlabeled or mislabeled specimen, insufficient volume, wrong tube, leakage, hemolysis, temperature excursion, delay beyond stability, missing requisition, and broken custody record. A rejection rate above 1–2% for a single courier or route should trigger investigation because it may indicate a systemic problem rather than isolated collection error.

Quarterly performance meetings with courier leadership should examine rejection trends, on-time pickup and delivery percentages, temperature exceptions, incident response times, corrective actions, and training records. Contracts should define measurable SLAs for scheduled pickup adherence, maximum transit time, temperature ranges, scan compliance, notification of delay, package integrity, after-hours escalation, disaster recovery, HIPAA confidentiality, DOT-trained personnel, and root-cause reporting. The agreement should also specify financial or operational remedies for repeated failures and a process for reviewing route changes before they affect stability windows.

To establish a compliant, monitored specimen transport program, submit a delivery inquiry or call (586) 204-7800.